Nowadays, HDAC inhibitors (HDACi), potential modifiers of histone acetylation, have been approved for the treatment of hematological malignancies, even though their application in atherosclerosis has not been investigated in clinical trials [122]. The gene discussed is HDAC9; the disease is atherosclerosis.